TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02634684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study: NCT04850131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desarda repair
Description: Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desarda repair
Description: Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
Study: NCT02845544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates-based exercises
Study: NCT02630550

Intervention type: DEVICE
Intervention: Cheetah NICOM
Description: The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.

Intervention type: DEVICE
Intervention: Cheetah NICOM
Description: The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.

Intervention type: DEVICE
Intervention: Transesophageal echocardiography (TEE)
Description: TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.

Intervention type: DEVICE
Intervention: Transesophageal echocardiography (TEE)
Description: TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
Study: NCT02653391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A Elamipretide 1.0% Ophthalmic Solution
Description: Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B Elamipretide 3.0% Ophthalmic Solution
Description: Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A Placebo
Description: Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
Study: NCT01938599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM001 Cream, 7.5%
Description: Cream, 2x daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AM001 Cream
Description: Cream, 2x daily for 12 weeks
Study: NCT03836612

Intervention type: OTHER
Intervention: No intervention
Description: Observation of routine clinical practice

Intervention type: OTHER
Intervention: No intervention
Description: Observation of routine clinical practice
Study: NCT00948623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham counseling program
Study: NCT01793675

Intervention type: PROCEDURE
Intervention: transplant with haploidentical donor
Description: patients with advanced MDS without identical sibling donor receive haploidentical transplant
Study: NCT03280914

Intervention type: DEVICE
Intervention: Auto-CPAP
Description: Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
Study: NCT04413409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy for the metastatic sites
Description: patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
Study: NCT03645980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Description: DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
Study: NCT00132145

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vascular Management Program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical Care Coordinators

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based Vascular Tracker for Patient and Physician

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Automated Telephone Reminder System
Study: NCT03590145

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
Study: NCT04502953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical plication
Description: Vertical plication of the rectovaginal septum was done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal plication
Description: Horizontal plication of the rectovaginal septum was done
Study: NCT01693926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute physical activity intervention
Description: 25 min of physical activity. The placebo arm will have 25 min of reading.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04316754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group.
Study: NCT03080545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar 0.005%-0.064% Topical Foam
Description: Topical foam
Study: NCT01410409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Study: NCT00658593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT02044601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
Study: NCT00658593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT01550380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
Study: NCT03838133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin®
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (0.9% sodium chloride, 10ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 50 mg (0.5%, 10 mL)
Study: NCT01918761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib, Pemetrexed
Description: Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
Study: NCT02436889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate
Study: NCT02725593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin placebo
Description: matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Study: NCT01244633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 50 or 100 mg tablets given once per day for eight weeks
Study: NCT04412213

Intervention type: OTHER
Intervention: Stuttering severity instrument for school-age children (SSI-3 Arabic version)
Description: Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)

Intervention type: OTHER
Intervention: Stuttering severity instrument for school-age children (SSI-3 Arabic version)
Description: Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
Study: NCT03407053

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-processed diet
Description: Consuming ultra-processed diet over a 2-week period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-processed diet
Description: Consuming ultra-processed diet over a 2-week period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unprocessed diet
Description: Consuming unprocessed diet over a 2-week period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unprocessed diet
Description: Consuming unprocessed diet over a 2-week period
Study: NCT04375605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study: NCT03835585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gun lock
Description: A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suicide Risk Assessment
Description: Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suicide Risk Assessment
Description: Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
Study: NCT00660907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glipizide
Description: Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Study: NCT04375605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate
Description: Day 1 q2w: 200 mg/m² IV over 2 hours
Study: NCT00660907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride
Description: Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Study: NCT02975778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Monitor™
Description: Pain measured by Pain Monitor™
Study: NCT04053075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine cluster detection
Description: Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced cluster detection
Description: Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
Study: NCT01410409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Study: NCT04375605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Day 1 q2w: 200 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 2 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin during radiotherapy
Description: Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil during radiotherapy
Description: day 1 - 33: 225 mg/m²/day IV continuously
Study: NCT01410409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day
Study: NCT03147612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given via central catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01635816

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE Vaccine existing facility
Description: Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
Study: NCT03147612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT01635816

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 1
Description: Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 2
Description: Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 3
Description: Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
Study: NCT00423371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.